<DOC>
	<DOCNO>NCT03026348</DOCNO>
	<brief_summary>This randomize , observer-blind , trial clinically-stable older adult . Up 300 eligible old adult 60 80 year age enrol 1:1 ratio multiple dose/formulation treatment arm . Safety immunogenicity data Day 56 use select vaccine candidate potentially evaluate Part 2 study . Proportions subject various stratum pre-specified goal achieve approximately equal distribution subject characteristics across treatment group . Serology measure consistent study outcomes report .</brief_summary>
	<brief_title>Safety Immunogenicity Study Evaluate Single- Two-Dose Regimens Of RSV F Vaccine With Without Aluminum Phosphate Matrix-M1™ Adjuvants In Clinically-Stable Older Adults</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>1 . Males females 60 80 year age ambulatory live community assistedliving facility provide minimal assistance , subject primarily responsible selfcare activity daily live . Subjects may one chronic medical diagnosis , clinically stable assess : Absence change medical therapy within one month due treatment failure toxicity ( dose adjustment ongoing therapy optimal effect , replacement within class drug due convenience cost , deem acceptable ) , Absence medical event qualify SAEs within one month plan vaccination Day 0 , Absence know , current , lifelimiting diagnosis , opinion investigator , render survival completion protocol unlikely . 2 . Willing able ( physical cognitive basis ) give inform consent prior study enrollment . To complete consent process , qualify subject correctly answer least 4 5 question informed consent form ( ICF ) comprehension assessment 2 attempt . 3 . Able comply study requirement . As protocol procedure involve telephone contact safety ascertainment , eligible subject must reliable access telephone . 1 . Received prior RSV vaccine . 2 . Participation research involve additional investigational product ( drug / biologic / device ) within 45 day plan date first vaccination . 3 . History serious reaction prior vaccination history GuillainBarré syndrome ( GBS ) within 6 week prior influenza immunization . 4 . Receipt inactivate influenza vaccine within 14 day prior Day 0 dose test article vaccine within 4 week prior Day 0 dose test article . 5 . Any known suspected immunosuppressive condition , acquire congenital , determined history and/or physical examination . 6 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥ 10 mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 7 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . 8 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature ≥ 38.0°C planned day vaccine administration ) . 9 . Known disturbance coagulation . Potential subject receive aspirin , clopidogrel , prasugrel , dipyridamole , dabigatran , apixaban , rivaroxaban , warfarin good control cardiovascular prophylaxis prophylaxis thromboembolic disease stroke set atrial fibrillation NOT exclude . 10 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse . 11 . Any condition opinion investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include neurologic , cognitive , psychiatric condition deem likely impair quality study compliance safety reporting ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>RSV</keyword>
</DOC>